Pasi A. Jänne, MD, PhD, senior vice president for Translational Medicine, director of the Belfer Center for Applied Cancer Science, director of the Chen-Huang Center for EGFR Mutant Lung Cancers, a senior physician, and the David M. Livingston, MD, Chair at Dana-Farber Cancer Institute; as well as a professor of medicine at Harvard Medical School, discussed notable recent changes to the second-line treatment paradigm for patients with EGFR-mutated non–small cell lung cancer (NSCLC). He also explained disease features that factor into his treatment decision-making process in the second-line EGFR-mutated NSCLC setting.